Lugano, Switzerland (ots) - Starting July 1st the Swiss Group has become Gold sponsor of the Sharing Progress in Cancer Care (SPCC) Programme Through its support to the Sharing Progress in Cancer Care (SPCC) Programme, Helsinn Group starts to actively collaborate with the European School of Oncology (ESO) in promoting education in oncology, with special attention to cancer supportive care. SPPC is a collaborative ...
Lugano (ots) - Considerable inflow of net new money: CHF 6.7 billion (+8.8%). CHF 77.7 billion in assets under management - Considerable inflow of net new money: CHF 6.7 billion (+8.8%). Assets under management stood at CHF 77.7 billion, up 1.9% despite the appreciation of the Swiss franc and the continuing negative trend on the financial markets - Continued successful expansion in fast-growing markets: Asia, Latin ...
Lugano, Switerland (ots) - The Company has entered the Phase III clinical program for both its investigational medications anamorelin, in non-small cell lung cancer-associated anorexia/cachexia, and netupitant + palonosetron oral fixed-dose combination in chemotherapy-induced nausea and vomiting (CINV) Helsinn, the Swiss pharmaceutical Group, global leader in the segment of the prevention of chemotherapy-induced nausea ...
Lugano, Switzerland and Woodcliff Lake, NJ, USA (ots) - Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and ...